BLRX Form 6-K adds Q3 2025 results to effective registrations

Rhea-AI Filing Summary

BioLineRx Ltd. filed a Form 6-K as a foreign private issuer reporting that it released its financial results for the three and nine months ended September 30, 2025. The company is furnishing a press release, unaudited condensed consolidated interim financial statements, and an operating and financial review for this period. These materials, including the section titled “Financial Results for the Quarter Ended September 30, 2025,” are incorporated by reference into all of its effective registration statements under the Securities Act of 1933.

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16 OF

THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2025

Commission file number: 001-35223

BioLineRx Ltd.

(Translation of registrant’s name into English)

2 HaMa’ayan Street

Modi’in 7177871, Israel

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒         Form 40-F ☐

On November 24, 2025, the Registrant issued a press release announcing its financial results for the three and nine months ended September 30, 2025. The Registrant is also publishing its unaudited interim consolidated financial statements, as well as its operating and financial review, as of September 30, 2025 and for the three and nine months then ended. Attached hereto are the following exhibits:

Exhibit 1: Registrant’s press release dated November 24, 2025;

Exhibit 2: Registrant’s condensed consolidated interim financial statements as of September 30, 2025 and for the three and nine months then ended; and

Exhibit 3: Registrant’s operating and financial review as of September 30, 2025 and for the three and nine months then ended.

This Form 6-K, the text under the heading “Financial Results for the Quarter Ended September 30, 2025” in Exhibit 1, Exhibit 2 and Exhibit 3 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	BioLineRx Ltd.
	By:	/s/ Philip A. Serlin
		Philip A. Serlin
		Chief Executive Officer

Dated: November 24, 2025

FAQ

What did BioLineRx (BLRX) report in its November 2025 Form 6-K?

BioLineRx reported that it issued a press release announcing its financial results for the three and nine months ended September 30, 2025, and furnished related interim financial statements and an operating and financial review.

Which financial periods does BioLineRx (BLRX) cover in this Form 6-K?

The Form 6-K covers BioLineRx’s financial results for the three and nine months ended September 30, 2025, including unaudited condensed consolidated interim financial statements for those periods.

What exhibits are attached to BioLineRx’s November 24, 2025 Form 6-K?

The filing includes three exhibits: a press release dated November 24, 2025, condensed consolidated interim financial statements as of September 30, 2025 and for the three and nine months then ended, and an operating and financial review for the same periods.

How does this BioLineRx (BLRX) Form 6-K affect its registration statements?

This Form 6-K, the text under the heading “Financial Results for the Quarter Ended September 30, 2025” in the press release, and the attached financial statements and review are incorporated by reference into all effective registration statements filed by BioLineRx under the Securities Act of 1933.

Who signed the BioLineRx (BLRX) Form 6-K filed in November 2025?

The Form 6-K was signed on behalf of BioLineRx Ltd. by Philip A. Serlin, its Chief Executive Officer.

Is BioLineRx (BLRX) a foreign private issuer and which annual report form does it use?

BioLineRx is identified as a foreign private issuer in this Form 6-K and indicates that it files annual reports under cover of Form 20-F.